Le Lézard
Classified in: Health
Subjects: NPT, STP, AVO

Petition filed by Three Nonprofit Groups Asking FTC to Investigate Maine Dental Board for Antitrust Violation


AUGUSTA, Maine, Oct. 31, 2019 /PRNewswire/ -- Three national nonprofits have petitioned the Federal Trade Commission (FTC) to investigate the Maine Board of Dental Practice for antitrust violations. According to the petition, https://tinyurl.com/FTC-MEdentalboard, the dental board refuses to enforce the state's fact sheet law. As a result, some dentists who still use dental amalgam are withholding information from patients about amalgam's mercury content.

Consumers for Dental Choice, Organic Consumers Association and Mercury Policy Project state in their petition that the Maine board engages in a variety of actions1 to evade enforcing the state law requiring every dentist who uses amalgam to give patients a state-approved fact sheet. 

"The Maine Dental Board is not above the law," said Katherine Paul of Freeport, Maine, speaking for Organic Consumers Association. "As with any other state agency, the board must support, enforce and adhere to the law." If this board doesn't want to fulfill its duty, Maine's Governor should appoint a new dental board."

"The behavior of the Maine dental board raises serious antitrust questions because the board is protecting the income of the pro-mercury dentists," said Charles Brown of Consumers for Dental Choice and a former antitrust law specialist. "This board must redirect its loyalty from protecting sales of amalgam to protecting Maine's families and consumers."  

"Dental amalgam is a major mercury pollution source worldwide resulting from its continuing use in Maine and elsewhere," said Michael Bender of the Mercury Policy Project.   "Consumers must be told that amalgam is mainly mercury, but also that there are nonmercury alternatives available that work just as well or better."

The petitioners note that use of the term "silver fillings" instead of "amalgam" deceives patients.

1 For example, the dental board advises dentists that compliance with the mandate is optional (although it is required), and the board held a secret vote to ally with the Maine Dental Association to defeat a state law that would shift MaineCare to mercury-free dentistry. The dental board has proposed a rule regarding disclosure, but it fails even to mention the Maine fact sheet law or the official fact sheet, which was written by then Director of Health Dora Mills.

Contact:
--Katherine Paul, Organic Consumers Ass'n, katherine@organicconsumers.org, 207.653.3090
--Charles Brown, Consumers for Dental Choice, charlie@mercury-free.org, 202.544.6333
--Michael Bender, Mercury Policy Project, mercurypolicy@aol.com, 802.917.8222      

SOURCE Consumers for Dental Choice


These press releases may also interest you

at 02:05
Today, Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the...

at 02:05
Masimo today announced the results of a study published in Pneumonia in which independent researchers in New Delhi, India, investigated the accuracy of Masimo RRp® on pediatric patients with the Rad-Gtm Pulse Oximeter by comparing it to...

at 02:00
With one in five people suffering from the annual attack of itchy red eyes and constant sneezing, and with the pollen count set for HIGH, on-demand laundry app, Laundrapp, shares its top five tips ? from bedding to intimacy ? for protecting against...

at 01:35
Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ? ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders,...

at 01:35
Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central...

at 01:00
Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company developing novel therapies for cancers, chronic hepatitis B (CHB), and senesce diseases, today announced a clinical collaboration with MSD to evaluate the combination of...



News published on 31 october 2019 at 08:03 and distributed by: